TYRA

Tyra Biosciences, Inc. TYRA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-45.56M

Quarter to Jun 30

Free cash flow

$-31.14M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.21B total
RA CAPITAL MANAGEMENT, L.P.
$389.62M0.0%
FMR LLC
$284.92M+15.1%
Jupiter Topco LLC
$139.16M--
Alta Partners Management Company, L.P.
$122.12M0.0%
Nextech Invest, Ltd.
$113.50M-12.4%
TCG Crossover Management, LLC
$103.77M0.0%
BlackRock, Inc.
$96.84M+36.7%
PRICE T ROWE ASSOCIATES INC /MD/
$88.88M+182.2%
STATE STREET CORP
$68.36M+76.0%
Commodore Capital LP
$59.89M-24.2%
Paradigm Biocapital Advisors LP
$58.41M-11.0%
VANGUARD CAPITAL MANAGEMENT LLC
$48.18M+34.0%
BVF INC/IL
$47.15M-25.3%
5AM Venture Management, LLC
$32.88M0.0%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$32.48M+85.2%
Hood River Capital Management LLC
$32.48MNew
GEODE CAPITAL MANAGEMENT, LLC
$31.01M+47.4%
Caligan Partners LP
$25.78M-36.8%
Canaan Partners XI LLC
$23.95M0.0%
Siren, L.L.C.
$23.16MNew
Sio Capital Management, LLC
$22.21M+14.8%
StemPoint Capital LP
$20.21M+227.6%
MARSHALL WACE, LLP
$18.63M+194.9%
GOLDMAN SACHS GROUP INC
$14.80M-15.8%
JENNISON ASSOCIATES LLC
$14.40M-28.7%
See all 170 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/TYRA

Earnings Per Share

13fpro.ai/company/TYRA

Loading ratio trend…

TYRA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Tyra Biosciences, Inc. (TYRA): stock profile, AI score and financials

Tyra Biosciences, Inc. (TYRA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. TYRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Tyra Biosciences, Inc. reports net income of $-45.6M, free cash flow of $-31.1M. Top institutional holders of TYRA by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., FMR, Jupiter Topco, based on the most recent SEC filings. TYRA trades on the Nasdaq exchange and files with the SEC under CIK 1863127. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TYRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tyra Biosciences, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1863127 →